The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Bupivacaine Hci · BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL · Injection, Solution · Infiltration; Perineural · HF Acquisition Co LLC, DBA HealthFirst
NDC 51662-1581-03 · 25 POUCH in 1 CASE / 1 VIAL, MULTI-DOSE in 1 POUCH / 50 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| HF Acquisition Co LLC, DBA HealthFirst | BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Bupivacaine Hci — NDC 51662-1581-03," retrieved September 3, 2026, https://drugdashboards.com/drug/51662158103.
Free to cite with attribution — see how the data is put together.